Red Blood Cell Disguise Edges Out PEG in Head-to-Head Test of Stealth Nanoparticles

For two decades, the dominant trick for keeping drug-carrying nanoparticles alive in the bloodstream has been to coat them with polyethylene glycol, a synthetic polymer that persuades the immune system to look the other way. Now a team at Fujian Medical University has run one of the most controlled comparisons yet between that industry standard and a rival approach borrowed from biology itself: wrapping nanoparticles in fragments of red blood cell membrane. Their findings, published in the Journal of Pharmaceutical Investigation, show that while both strategies work, the biomimetic camouflage consistently outperformed PEGylation across a battery of in vitro and in vivo tests, offering some of the clearest evidence to date that the choice of stealth coating can meaningfully shape cancer therapy outcomes.

The central problem the researchers set out to address is deceptively simple to state but notoriously difficult to study. When nanoparticles enter the bloodstream, the reticuloendothelial system, a network of macrophage-rich organs dominated by the liver and spleen, recognizes them as foreign material and clears them within minutes to hours. A nanoparticle that is removed from circulation before it can reach a tumor delivers little drug to the disease and much to healthy tissue, compounding toxicity while blunting efficacy. Both PEGylation and red blood cell membrane coating are designed to defeat this clearance, but they do so through entirely different chemistry. PEG is a hydrophilic synthetic polymer that forms a hydration shell around particles, sterically blocking the adsorption of opsonins, the blood proteins that flag foreign material for destruction. Red blood cell membranes, by contrast, carry native ‘self’ markers, most famously the CD47 protein, which engages an inhibitory receptor on macrophages and delivers a molecular ‘don’t eat me’ signal. Yet despite the popularity of both approaches, the field has lacked rigorous head-to-head comparisons in which the only variable is the coating itself.

That gap is precisely what the Fujian team, led by Han Lin, Xiaoqin Wang, and corresponding author Qing Hu, set out to close. Their experimental design hinged on a single, identical nanocarrier core: albumin nanoparticles loaded with doxorubicin, a widely used chemotherapy agent. Albumin has become an attractive scaffold for drug delivery because it is biocompatible, biodegradable, and has a natural affinity for tumors, which scavenger albumin as a nutrient source. Building on this shared platform, the researchers constructed three formulations that differed only in their outermost surface. The first was the bare doxorubicin-loaded albumin nanoparticle, designated DOX-BSA, serving as the unmodified control. The second, DOX-BSA@LPs, was cloaked in PEGylated liposomes, representing the synthetic stealth strategy. The third, DOX-BSA@RMs, was camouflaged with red blood cell membranes, representing the biomimetic strategy. Because all three shared the same core, the same drug payload, and the same underlying particle, any differences in biological behavior could be attributed to the coating rather than to confounding variations in size, charge, or drug loading.

The team then subjected all three formulations to a systematic evaluation spanning physicochemical characterization, cellular behavior, tumor accumulation, and therapeutic performance. The physicochemical work confirmed that the coatings had been successfully applied and that the formulations were suitable for comparison, while the biological assays probed the questions that matter most for nanomedicine: how readily tumor cells take the particles up, how deeply the particles penetrate into tumor-like tissue, how much drug actually accumulates in tumors relative to healthy organs, and ultimately how well the treatments shrink tumors in living animals.

The first headline result was that both stealth strategies clearly worked. Compared with the unmodified DOX-BSA nanoparticles, both the PEGylated liposome-coated and the red blood cell membrane-coated versions showed significantly enhanced tumor accumulation and significantly improved anti-tumor efficacy, with the differences reaching statistical significance at the P < 0.05 threshold. This confirms, on a controlled albumin platform, the core premise of stealth nanotechnology: disguising the surface of a nanocarrier allows it to evade immune clearance long enough to reach its target. For a field in which many comparisons are confounded by differences in particle design, this clean demonstration of the stealth effect itself is a valuable benchmark.

But the more provocative finding lay in the comparison between the two coatings. Across multiple endpoints, the red blood cell membrane formulation, DOX-BSA@RMs, showed marginal yet statistically significant advantages over its PEGylated counterpart, DOX-BSA@LPs. In three-dimensional tumor spheroids, laboratory models that mimic the dense, poorly vascularized architecture of real tumors, the membrane-camouflaged particles penetrated deeper than the PEGylated ones. Penetration depth is a critical variable in solid tumor therapy because chemotherapeutics must reach not just the cells at the tumor periphery but the inner mass, where hypoxic and quiescent cells often survive treatment and seed relapse. A coating that improves access to the tumor interior could therefore translate into more complete tumor kill.

Histological examination of treated tumors reinforced the pattern. Tumors from animals treated with the red blood cell membrane formulation displayed more extensive necrosis and apoptosis, the two hallmarks of effective chemotherapy response, than tumors treated with the PEGylated formulation. Consistent with this, the membrane-coated particles achieved a higher tumor inhibition rate overall, meaning they shrank tumors more effectively in vivo. The researchers also measured tumor-to-normal-tissue ratios, a pharmacokinetic metric that captures how selectively a formulation homes in on tumors versus healthy organs, and found the ratios were superior for the membrane-camouflaged particles, indicating higher tumor accumulation relative to off-target deposition. Higher selectivity is the holy grail of chemotherapy, since it promises greater efficacy with fewer of the dose-limiting side effects, such as cardiotoxicity, that plague conventional doxorubicin.

Why might a biological membrane outperform a synthetic polymer, even if only by a modest margin? The authors’ findings are consistent with mechanistic ideas that have been accumulating in the literature. PEG, despite its success in products such as the liposomal doxorubicin formulation Doxil, the first FDA-approved nano-drug, is not without liabilities. Anti-PEG antibodies exist in a substantial fraction of the population, likely owing to widespread exposure to PEG-containing products, and recent work has shown that such antibodies can become enriched in the protein corona that forms around PEGylated nanocarriers, potentially accelerating clearance and altering cellular uptake on repeated dosing. Red blood cell membranes, by contrast, present a native repertoire of self-markers, including CD47, whose role as a ‘marker of self’ on erythrocytes was established in landmark work published in Science in 2000. In addition, membrane coatings preserve the mechanical deformability that allows red blood cells to squeeze through narrow capillaries, a property that some studies suggest may aid circulation and tissue penetration in ways that rigid synthetic coatings cannot replicate.

The significance of the study lies as much in its methodology as in its results. By fixing the core and varying only the coating, the researchers established what they describe as a comparative paradigm for evaluating nano-coatings, one that removes the confounders that have made it difficult to judge competing stealth strategies on their merits. Previous reviews of the field, including a 2024 analysis of stealth coatings in cancer models published in ACS Applied Materials and Interfaces, have noted that direct comparisons under uniform conditions are rare, leaving formulators to choose between PEGylation and membrane coating largely on the basis of precedent rather than evidence. The Fujian study provides that evidence for the albumin-doxorubicin system, and its framework can be readily applied to other payloads and other coating chemistries, from macrophage membranes to platelet membranes to hybrid coatings that combine features of several cell types.

Caveats remain, as they always do in preclinical nanomedicine. The advantages of the red blood cell membrane coating, while statistically significant, were described by the authors as marginal in magnitude, and the study evaluated a single drug, a single core material, and a single tumor model. Red blood cell membrane coatings also raise practical questions about sourcing, standardization, and scale-up that synthetic polymers do not, and the long-term immunological behavior of membrane-cloaked particles in repeat-dose regimens will require further study. Nevertheless, the work marks an important step toward rational, evidence-based design of nanocarrier surfaces. As cancer nanomedicine matures from proof-of-concept demonstrations toward optimized clinical formulations, studies that isolate the contribution of each design choice, rather than changing everything at once, are exactly what the field needs. On the evidence assembled by the Fujian Medical University team, when it comes to hiding a nanoparticle from the immune system long enough to deliver a lethal payload to a tumor, nature’s own disguise appears to hold a slight but real edge over the best synthetic imitation.

Subject of Research: Comparison of PEGylation and red blood cell membrane stealth coatings on doxorubicin-loaded albumin nanoparticles for antitumor drug delivery

Article Title: Comparison of PEGylation versus red blood cell membrane camouflage strategies: in vivo and in vitro antitumor efficacy of doxorubicin-loaded albumin nanoparticles

Article References: Lin, H., Wang, X., Lin, Z., Dai, T., Qiu, X., Yu, X., Yu, Y., & Hu, Q. (2026). Comparison of PEGylation versus red blood cell membrane camouflage strategies: in vivo and in vitro antitumor efficacy of doxorubicin-loaded albumin nanoparticles. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00831-4

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00831-4

Keywords: nanoparticles, drug delivery, PEGylation, red blood cell membrane, doxorubicin, albumin nanoparticles, stealth coating, tumor accumulation, cancer therapy, nanomedicine, biomimetic coating, CD47